BillionToOne
PublicBillionToOne is now publicly traded
The data on this page reflects BillionToOne's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series D
Jun 21, 2024
Est. Valuation at Exit
$1B
Total Funding Raised
$426.22M
Company Overview
BillionToOne operates in Healthcare/Wellness and is based in Menlo Park, California. It has raised $426.22M.
BillionToOne is a molecular diagnostics company that develops ultrasensitive prenatal and oncology assays for precise detection of genetic disorders and tumor profiling from blood samples.
Sector
Healthcare/Wellness
Verticals
FemTech, Life Sciences, LOHAS & Wellness, Oncology
AI Layer
Non-AI
BillionToOne Comparables
Compare BillionToOne with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Natera, Inc. | 84% | |
| Myriad Genetics | 83% | |
| Labcorp | 78% |
For institutional investors. Book with your work email.
BillionToOne Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jun 21, 2024 | ||||
| Series C Extension | Dec 15, 2022 | ||||
| Debt | Dec 15, 2022 | ||||
| Series C | Mar 30, 2022 | ||||
| Series B | Jun 14, 2021 | ||||
Series A Extension | Mar 10, 2020 |
For institutional investors. Book with your work email.
BillionToOne Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pacific 8 Ventures | Series C, Series A Extension |
| Time BioVentures | Series C, Series C Extension |
| NIH RADx | Grant |
| 500 Global | Seed |
| Neuberger Berman | Series D |
| Norwest Venture Partners | Series B, Series C, Series D, Series C Extension |
| Fark Labs | Series C |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenue_increased_byNov 4, 2026
BillionToOne Inc. increases third-quarter revenue by 47% year over year to $123 million and raises its 2026 revenue outlook to $460 million-$470 million.
- launchesNov 4, 2026
BillionToOne Inc. plans to commercially launch Northstar Clear, a tissue-free molecular residual disease test available for all solid tumors at launch, on Dec 15th '26.
- has_revenueOct 14, 2026
BillionToOne Inc. raises its 2026 revenue outlook to $460 million-$470 million, including $465M, after third-quarter revenue rises 47% to $123 million on Nov 4th '26.
For institutional investors. Book with your work email.
BillionToOne Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.